Purpose: The purpose of this study is to investigate the stress response and sleep state of the new patients who visit the hospital for prosthodontic treatment due to tooth loss to make reference to further treatment direction. Materials and methods: Examinations, consultations, and surveys were conducted on 236 patients (94 males, 142 females, and 24-86 years old), who newly registered at the department of prosthodontics at Pusan national university hospital, for 2 years from 2018. The number of remaining teeth, edentulous arch, possibility of mastication, and future prosthetic treatment directions were recorded. The visual analogue scale (VAS), stress response inventory (SRI) and Insomnia severity index (ISI) were used as tools to measure patient’s subjective discomfort, stress response, and sleep status. Results: Among the entire prosthodontic patient group, the average value of ‘fatigue’ was significantly higher among the 7 items of SRI, and the value of ‘aggression’ was significantly lower (P<.001). There are a significant difference between the edentulous and full dentition in the oral discomfort value measured by VAS (P=.004). In cases where less than 20 teeth remain, mastication is impossible, and patients who are planning treatment with removable prostheses, VAS value and ‘depression’ and ‘fatigue’ values in SRI were higher than those in the reverse case (P<.05).The patients showed severe level in VAS value have high value of ‘tension’, ‘somatization’, ‘depression’, ‘fatigue’and ‘frustration’in SRI than non-serious patients (P<.05). Clinical insomnia occurred in 11.4% of all patients, and women had significantly lower sleep quality than men (P=.044). Patients with insomnia showed significantly higher scores on the VAS value and all 7 SRI items than those of normal sleepers (P<.05). Conclusion The new prosthetics had high ‘fatigue’ value among the 7 items of SRI. The oral condition, number of residual teeth and mastication function and clinical insomnia affected oral discomfort and the stress response.

Purpose: The purpose of this study is to investigate the stress response and sleep state of the new patients who visit the hospital for prosthodontic treatment due to tooth loss to make reference to further treatment direction. Materials and methods: Examinations, consultations, and surveys were conducted on 236 patients (94 males, 142 females, and 24-86 years old), who newly registered at the department of prosthodontics at Pusan national university hospital, for 2 years from 2018. The number of remaining teeth, edentulous arch, possibility of mastication, and future prosthetic treatment directions were recorded. The visual analogue scale (VAS), stress response inventory (SRI) and Insomnia severity index (ISI) were used as tools to measure patient’s subjective discomfort, stress response, and sleep status. Results: Among the entire prosthodontic patient group, the average value of ‘fatigue’ was significantly higher among the 7 items of SRI, and the value of ‘aggression’ was significantly lower (P<.001). There are a significant difference between the edentulous and full dentition in the oral discomfort value measured by VAS (P=.004). In cases where less than 20 teeth remain, mastication is impossible, and patients who are planning treatment with removable prostheses, VAS value and ‘depression’ and ‘fatigue’ values in SRI were higher than those in the reverse case (P<.05).The patients showed severe level in VAS value have high value of ‘tension’, ‘somatization’, ‘depression’, ‘fatigue’and ‘frustration’in SRI than non-serious patients (P<.05). Clinical insomnia occurred in 11.4% of all patients, and women had significantly lower sleep quality than men (P=.044). Patients with insomnia showed significantly higher scores on the VAS value and all 7 SRI items than those of normal sleepers (P<.05). Conclusion The new prosthetics had high ‘fatigue’ value among the 7 items of SRI. The oral condition, number of residual teeth and mastication function and clinical insomnia affected oral discomfort and the stress response.

Objective: The long-term efficacy of radiofrequency ablation (RFA) for the treatment of benign thyroid nodules remains unclear. We aimed to evaluate the long-term efficacy, emphasizing single-session RFA, and identify the factors associated with cases requiring additional RFA sessions to achieve a comparable volume reduction rates (VRR). Materials and Methods: We retrospectively evaluated benign thyroid nodules treated with RFA between 2008 and 2018.Treatment efficacy at the 5- and 10-year follow-ups was analyzed. Additionally, subgroup analysis comparing technique efficacy, such as the final VRR, between the single- and multi-session RFA groups was performed. Continuous variables were analyzed using the two-sample t-test or Mann–Whitney U test, and categorical variables were analyzed using the Chi-square or Fisher’s exact test. Results: A total of 267 nodules from 237 patients (age: 46.3 ± 15.0 years; female: 210/237 [88.6%]) were included. Of these, 60 were analyzed for the 5-year follow-up (mean follow-up duration ± standard deviation: 5.8 ± 0.4 years) and 29 for the 10-year follow-up (10.9 ± 0.9 years). Single-session RFA showed a median VRR of 95.7% (5th year) and 98.8% (10th year), while multi-session RFA showed comparable median VRRs of 97.4% (5th year) and 96.9% (10th year). The vascularity type, demographic factors, nodular components, and locations did not significantly differ between the single-session and multisession RFA groups. However, nodules with pre-RFA volume <10 mL were more prevalent in the single-session RFA group than in the multi-session RFA group (5th year: 64.3% [18/28] vs. 34.4% [11/32], P = 0.040; 10th year: 75.0% [12/16] vs. 23.1% [3/13], P = 0.016). Conclusion Single-session RFA may be sufficient for achieving adequate volume reduction during long-term follow-up for small-volume benign thyroid nodules. A high VRR was maintained regardless of the nodular component, location, demographic factors, or vascularity type. However, large-volume nodules may require multiple RFA sessions to achieve a comparable VRR.

Objective: The long-term efficacy of radiofrequency ablation (RFA) for the treatment of benign thyroid nodules remains unclear. We aimed to evaluate the long-term efficacy, emphasizing single-session RFA, and identify the factors associated with cases requiring additional RFA sessions to achieve a comparable volume reduction rates (VRR). Materials and Methods: We retrospectively evaluated benign thyroid nodules treated with RFA between 2008 and 2018.Treatment efficacy at the 5- and 10-year follow-ups was analyzed. Additionally, subgroup analysis comparing technique efficacy, such as the final VRR, between the single- and multi-session RFA groups was performed. Continuous variables were analyzed using the two-sample t-test or Mann–Whitney U test, and categorical variables were analyzed using the Chi-square or Fisher’s exact test. Results: A total of 267 nodules from 237 patients (age: 46.3 ± 15.0 years; female: 210/237 [88.6%]) were included. Of these, 60 were analyzed for the 5-year follow-up (mean follow-up duration ± standard deviation: 5.8 ± 0.4 years) and 29 for the 10-year follow-up (10.9 ± 0.9 years). Single-session RFA showed a median VRR of 95.7% (5th year) and 98.8% (10th year), while multi-session RFA showed comparable median VRRs of 97.4% (5th year) and 96.9% (10th year). The vascularity type, demographic factors, nodular components, and locations did not significantly differ between the single-session and multisession RFA groups. However, nodules with pre-RFA volume <10 mL were more prevalent in the single-session RFA group than in the multi-session RFA group (5th year: 64.3% [18/28] vs. 34.4% [11/32], P = 0.040; 10th year: 75.0% [12/16] vs. 23.1% [3/13], P = 0.016). Conclusion Single-session RFA may be sufficient for achieving adequate volume reduction during long-term follow-up for small-volume benign thyroid nodules. A high VRR was maintained regardless of the nodular component, location, demographic factors, or vascularity type. However, large-volume nodules may require multiple RFA sessions to achieve a comparable VRR.

Objective: The long-term efficacy of radiofrequency ablation (RFA) for the treatment of benign thyroid nodules remains unclear. We aimed to evaluate the long-term efficacy, emphasizing single-session RFA, and identify the factors associated with cases requiring additional RFA sessions to achieve a comparable volume reduction rates (VRR). Materials and Methods: We retrospectively evaluated benign thyroid nodules treated with RFA between 2008 and 2018.Treatment efficacy at the 5- and 10-year follow-ups was analyzed. Additionally, subgroup analysis comparing technique efficacy, such as the final VRR, between the single- and multi-session RFA groups was performed. Continuous variables were analyzed using the two-sample t-test or Mann–Whitney U test, and categorical variables were analyzed using the Chi-square or Fisher’s exact test. Results: A total of 267 nodules from 237 patients (age: 46.3 ± 15.0 years; female: 210/237 [88.6%]) were included. Of these, 60 were analyzed for the 5-year follow-up (mean follow-up duration ± standard deviation: 5.8 ± 0.4 years) and 29 for the 10-year follow-up (10.9 ± 0.9 years). Single-session RFA showed a median VRR of 95.7% (5th year) and 98.8% (10th year), while multi-session RFA showed comparable median VRRs of 97.4% (5th year) and 96.9% (10th year). The vascularity type, demographic factors, nodular components, and locations did not significantly differ between the single-session and multisession RFA groups. However, nodules with pre-RFA volume <10 mL were more prevalent in the single-session RFA group than in the multi-session RFA group (5th year: 64.3% [18/28] vs. 34.4% [11/32], P = 0.040; 10th year: 75.0% [12/16] vs. 23.1% [3/13], P = 0.016). Conclusion Single-session RFA may be sufficient for achieving adequate volume reduction during long-term follow-up for small-volume benign thyroid nodules. A high VRR was maintained regardless of the nodular component, location, demographic factors, or vascularity type. However, large-volume nodules may require multiple RFA sessions to achieve a comparable VRR.

Objective: The long-term efficacy of radiofrequency ablation (RFA) for the treatment of benign thyroid nodules remains unclear. We aimed to evaluate the long-term efficacy, emphasizing single-session RFA, and identify the factors associated with cases requiring additional RFA sessions to achieve a comparable volume reduction rates (VRR). Materials and Methods: We retrospectively evaluated benign thyroid nodules treated with RFA between 2008 and 2018.Treatment efficacy at the 5- and 10-year follow-ups was analyzed. Additionally, subgroup analysis comparing technique efficacy, such as the final VRR, between the single- and multi-session RFA groups was performed. Continuous variables were analyzed using the two-sample t-test or Mann–Whitney U test, and categorical variables were analyzed using the Chi-square or Fisher’s exact test. Results: A total of 267 nodules from 237 patients (age: 46.3 ± 15.0 years; female: 210/237 [88.6%]) were included. Of these, 60 were analyzed for the 5-year follow-up (mean follow-up duration ± standard deviation: 5.8 ± 0.4 years) and 29 for the 10-year follow-up (10.9 ± 0.9 years). Single-session RFA showed a median VRR of 95.7% (5th year) and 98.8% (10th year), while multi-session RFA showed comparable median VRRs of 97.4% (5th year) and 96.9% (10th year). The vascularity type, demographic factors, nodular components, and locations did not significantly differ between the single-session and multisession RFA groups. However, nodules with pre-RFA volume <10 mL were more prevalent in the single-session RFA group than in the multi-session RFA group (5th year: 64.3% [18/28] vs. 34.4% [11/32], P = 0.040; 10th year: 75.0% [12/16] vs. 23.1% [3/13], P = 0.016). Conclusion Single-session RFA may be sufficient for achieving adequate volume reduction during long-term follow-up for small-volume benign thyroid nodules. A high VRR was maintained regardless of the nodular component, location, demographic factors, or vascularity type. However, large-volume nodules may require multiple RFA sessions to achieve a comparable VRR.

Objective: The long-term efficacy of radiofrequency ablation (RFA) for the treatment of benign thyroid nodules remains unclear. We aimed to evaluate the long-term efficacy, emphasizing single-session RFA, and identify the factors associated with cases requiring additional RFA sessions to achieve a comparable volume reduction rates (VRR). Materials and Methods: We retrospectively evaluated benign thyroid nodules treated with RFA between 2008 and 2018.Treatment efficacy at the 5- and 10-year follow-ups was analyzed. Additionally, subgroup analysis comparing technique efficacy, such as the final VRR, between the single- and multi-session RFA groups was performed. Continuous variables were analyzed using the two-sample t-test or Mann–Whitney U test, and categorical variables were analyzed using the Chi-square or Fisher’s exact test. Results: A total of 267 nodules from 237 patients (age: 46.3 ± 15.0 years; female: 210/237 [88.6%]) were included. Of these, 60 were analyzed for the 5-year follow-up (mean follow-up duration ± standard deviation: 5.8 ± 0.4 years) and 29 for the 10-year follow-up (10.9 ± 0.9 years). Single-session RFA showed a median VRR of 95.7% (5th year) and 98.8% (10th year), while multi-session RFA showed comparable median VRRs of 97.4% (5th year) and 96.9% (10th year). The vascularity type, demographic factors, nodular components, and locations did not significantly differ between the single-session and multisession RFA groups. However, nodules with pre-RFA volume <10 mL were more prevalent in the single-session RFA group than in the multi-session RFA group (5th year: 64.3% [18/28] vs. 34.4% [11/32], P = 0.040; 10th year: 75.0% [12/16] vs. 23.1% [3/13], P = 0.016). Conclusion Single-session RFA may be sufficient for achieving adequate volume reduction during long-term follow-up for small-volume benign thyroid nodules. A high VRR was maintained regardless of the nodular component, location, demographic factors, or vascularity type. However, large-volume nodules may require multiple RFA sessions to achieve a comparable VRR.

Heterotopic pregnancy, the potentially fatal condition in which simultaneous gestations occurs at two or more implantation sites, was first reported in 1708 as an autopsy finding. In natural conception cycles it is a rare event, occuring less than 1:30,000 pregnancies. However, with assisted reproduction techniques, this incidence increase. Also the frequency of heterotopic pregnancy has steadily increased because of rising incidence of pelvic inflammatory disease, former tubal surgery. We report a case of discovery of heterotopic pregnancy after missed abortion with brief review of literature.
Abortion, Missed* ; Autopsy ; Female ; Fertilization ; Incidence ; Pelvic Inflammatory Disease ; Pregnancy ; Pregnancy, Heterotopic* ; Reproductive Techniques

The Shikani Optical Stylet(TM) (SOS, Clarus Medical, USA) is another tool to facilitate tracheal intubation. It combines the benefits of a lightwand and a fiberoptic bronchoscope. We report the application of SOS in facilitating the tracheal intubation of two-person with history of difficult airway management. A 25-year-old woman with micrognathia was scheduled to undergo an exploratory laparotomy. Intubation attemps failed with a direct laryngoscope because of difficulty in her mouth opening. Although airway management was re-attempted by a laryngeal mask airway, it also failed for the same reason. Airway management was successfully performed using the SOS instead of a laryngeal mask airway. The second case was a 38-year-old woman with ankylosing spondylitis, scheduled for spinal fusion. She had difficulty in extending her neck. Intubation was successfully performed via the SOS. We believe that intubation by the SOS is a useful and readily available alternative technique for patients with difficult airways.
Adult ; Airway Management ; Bronchoscopes ; Female ; Humans ; Intubation ; Laparotomy ; Laryngeal Masks ; Laryngoscopes ; Mouth ; Neck ; Spinal Fusion ; Spondylitis, Ankylosing

OBJECTIVE: This study was to investigate the generation of the functional neuron derived from human embryonic stem(hES,MB03) cells on in vitro neural cell differentiation system. METHODS: For neural progenitor cell formation derived from hES cells, we produced embryoid bodies (EB: for 5 days, without mitogen) from hES cells and then neurospheres (for 7~10 days, 20 ng/ml of bFGF added N2 medium) from EB. And then finally for the differentiation into mature neuron, neural progenitor cells were cultured in i) N2 medium only (without bFGF),ii) N2 supplemented with 20 ng/ml platelet derived growth factor-bb (PDGF-bb) or iii) N2 supplemented with 5 ng/ml brain derived neurotrophic factor (BDNF) for 2 weeks. Identification of neural cell differentiation was carried out by immunocytochemistry using betaIII-tubulin (1:100) and GFAP (1:500). Also, generation of functional neuron was identified using anti-glutamate (Sigma, 1:1000), anti-GABA (Sigma, 1:1000), anti-serotonin (Sigma, 1:1000) and anti-tyrosine hydroxylase (Sigma, 1:1000). RESULTS: In vitro neural cell differentiation, neurotrophic factors (PDGF and BDNF) treated cell groups were high expressed MAP-2 and GFAP than non-treated cell group. The highest expression pattern of MAP-2 and betaIII-tubulin was indicated in BDNF treated group. Also, in the presence of PDGF-bb or BDNF, mostof the neural cells derived from hES cells were differentiated into gultamate and GABA neuron in vitro. Furthermore, we confirmed that there were a few serotonin and tyrosine hydroxylase positive neuron in the same culture environment. CONCLUSION: This results suggested that the generation of functional neuron derived from hES cells was increased by addition of neurotrophic factors such as PDGF-bb or BDNF in b-FGF induced neural cell differentiation system and especially gultamate and GABA neurons were mainly produced in the system.
Blood Platelets ; Brain-Derived Neurotrophic Factor* ; Cell Differentiation* ; Embryoid Bodies ; Embryonic Stem Cells* ; gamma-Aminobutyric Acid ; Humans* ; Immunohistochemistry ; Nerve Growth Factors ; Neurons* ; Serotonin ; Stem Cells ; Tyrosine 3-Monooxygenase